RAD51 是一种必需的真核 DNA 重组酶,可在同源重组 (HR) 和双链断裂的重组修复过程中促进同源配对和链交换。BRCA2 将 RAD51 蛋白招募到 DNA 断裂处,形成同源聚合细丝,侵入同源染色单体并将其用作修复模板。RAD51 细丝可通过免疫荧光检测为细胞核中的不同焦点,它们的存在是 HR 能力的读数。RAD51 是一种必需基因,可保护细胞免受遗传不稳定的影响。
RAD51 重组酶活性对癌细胞增殖和存活起着关键作用,并且通常会导致耐药性。在包括乳腺癌和慢性粒细胞白血病 (CML) 在内的一组癌症中发现了异常升高的 RAD51 功能和过度活跃的同源重组 (HR) 率。因此,直接针对 RAD51 并减弱失调的 RAD51 活性被提议作为癌症治疗的替代和补充策略。
RAD51, an essential eukaryotic DNA recombinase, promotes homologous pairing and strand exchange during homologous recombination (HR) and the recombinational repair of double strand breaks. RAD51 protein is recruited onto the DNA break by BRCA2 and forms homopolymeric filaments that invade the homologous chromatid and use it as a template for repair. RAD51 filaments are detectable by immunofluorescence as distinct foci in the cell nucleus, and their presence is a read out of HR proficiency. RAD51 is an essential gene, protecting cells from genetic instability.
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML). Directly targeting RAD51 and attenuating the deregulated RAD51 activity has therefore been proposed as an alternative and supplementary strategy for cancer treatment.
LL-K12-18 是一种 CDK12 激酶抑制剂,也是一种双位点分子胶,它以 283.9 nM 的 IC50 值抑制人源 CDK12,并通过稳定 CDK12-DDB1 复合物经泛素-蛋白酶体系统选择性降解 cyclin K,同时下调 DNA 损伤应答基因、降低 RNA 聚合酶 II CTD Ser2 磷酸化水平并调节 ATM、RAD51、γ-H2AX 和剪切型 PARP 等标志物,从而有效诱导乳腺癌细胞凋亡 (apoptosis) 并抑制其增殖,且具有高度的靶向选择性,可用于三阴性乳腺癌的研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号